Halozyme, Inc.

Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®

Retrieved on: 
Thursday, November 5, 2020

The ANDROMEDA study will also be the subject of four poster presentations (Abstracts #1392, #1640, #1409 and #2305).

Key Points: 
  • The ANDROMEDA study will also be the subject of four poster presentations (Abstracts #1392, #1640, #1409 and #2305).
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.
  • Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.
  • Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

Retrieved on: 
Thursday, October 29, 2020

An archived webcast replay will be available on the Company's website from November 5, 2020, until November 12, 2020.

Key Points: 
  • An archived webcast replay will be available on the Company's website from November 5, 2020, until November 12, 2020.
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

Retrieved on: 
Tuesday, October 6, 2020

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.

Key Points: 
  • SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.
  • "We are pleased to be expanding the scope of our collaboration with Halozyme and to continue our productive relationship.
  • "We are delighted that argenx has agreed to expand our global collaboration and license agreement to include up to six targets," said Dr. Helen Torley, president and chief executive officer.
  • Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Volastra Therapeutics Appoints Charles Hugh-Jones as Chief Executive Officer

Retrieved on: 
Wednesday, September 16, 2020

Volastra Therapeutics, a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease, has named Charles Hugh-Jones, MD, FRCP, as its Chief Executive Officer.

Key Points: 
  • Volastra Therapeutics, a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease, has named Charles Hugh-Jones, MD, FRCP, as its Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20200916005142/en/
    Volastra CEO Charles Hugh-Jones (Photo: Business Wire)
    We are incredibly fortunate that Charles is joining the team.
  • He then joined Pfizer Oncology division as their Chief Medical Officer where he had medical oversight of all late-stage drug development and commercialization activities.
  • Volastra Therapeutics, is a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease.

Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis

Retrieved on: 
Thursday, September 10, 2020

"Patients diagnosed with AL amyloidosis currently have no approved therapeutic options and we are therefore pleased that a new treatment for the disease may soon be available."

Key Points: 
  • "Patients diagnosed with AL amyloidosis currently have no approved therapeutic options and we are therefore pleased that a new treatment for the disease may soon be available."
  • The RTOR program aims to explore a more efficient review process to help ensure treatments are available as soon as possible for patients.
  • Selection into the RTOR program does not guarantee or influence approvability of the supplemental application.
  • Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Halozyme To Present At Upcoming Virtual Investor Conferences

Retrieved on: 
Wednesday, September 9, 2020

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the following investor conferences:

Key Points: 
  • SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the following investor conferences:
    Cantor Virtual Global Healthcare Conference at 10:40 a.m.
  • ET / 7:40 a.m. PT on Tuesday, September 15, 2020
    Morgan Stanley Virtual Global Healthcare Conference at 2:00 p.m.
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.
  • Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference

Retrieved on: 
Wednesday, September 2, 2020

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference.

Key Points: 
  • SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference.
  • ET / 07:00 a.m. PT on Wednesday, September 9, 2020.
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.
  • Halozyme haslicensed its ENHANZE drug delivery technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference

Retrieved on: 
Tuesday, August 4, 2020

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference.

Key Points: 
  • SAN DIEGO, Aug. 4, 2020 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference.
  • To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.
  • Halozyme has licensed its ENHANZE drug delivery technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel

Retrieved on: 
Thursday, July 16, 2020

has joined the company as General Counsel and Chief Compliance Officer.

Key Points: 
  • has joined the company as General Counsel and Chief Compliance Officer.
  • Mr. Leonhardt most recently served as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary and a member of the executive committee for Halozyme Therapeutics, Inc. where he provided strategic counsel on a broad range of legal matters for the company and its board of directors.
  • Prior to that time, Mr. Leonhardt served as General Counsel for a number of San Diego-based biotech companies, and as Chief Litigation Counsel and later as General Counsel for the European Region at Allergan Pharmaceuticals.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel

Retrieved on: 
Thursday, July 16, 2020

has joined the company as General Counsel and Chief Compliance Officer.

Key Points: 
  • has joined the company as General Counsel and Chief Compliance Officer.
  • Mr. Leonhardt most recently served as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary and a member of the executive committee for Halozyme Therapeutics, Inc. where he provided strategic counsel on a broad range of legal matters for the company and its board of directors.
  • Prior to that time, Mr. Leonhardt served as General Counsel for a number of San Diego-based biotech companies, and as Chief Litigation Counsel and later as General Counsel for the European Region at Allergan Pharmaceuticals.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.